Michiels A, Hubens G, Ruppert M, Balliu L, Vaneerdeweg W
Department of Abdominal Surgery, University Hospital Antwerp, Edegem, Belgium.
Acta Chir Belg. 2007 Jul-Aug;107(4):468-71. doi: 10.1080/00015458.2007.11680102.
A case of a liposarcoma of the stomach in a 27-year old woman is described. Initially the patient consulted with epigastric pain. MRI showed a giant tumour of the stomach wall, invading the surrounding organs, as well as the mediastinal region. After surgical 'en-bloc' resection of the tumour, histopathologic examination yielded a diagnosis of pleiomorphic liposarcoma. Because of the bad prognosis of this histologic type, the patient received adjuvant chemotherapy: a combination of doxorubicin and ifosfamide (MAI). Nine months after surgery, she represented with a relapse of the tumour that had become inoperable. Palliative chemotherapy was started with the intent to prolong the young patient's life. However 6 months later, the patient died of the recurrent disease. Although liposarcoma is a very common soft tissue sarcoma, it is rarely seen in the stomach. The standard therapy is surgical excision. Over the last years, adjuvant therapy became more accepted. Drugs of choice are doxorubicin and ifosfamide, although the benefits of this therapy are still largely unknown and doubtful.
本文描述了一例27岁女性胃脂肪肉瘤病例。患者最初因上腹部疼痛就诊。磁共振成像(MRI)显示胃壁有一个巨大肿瘤,侵犯周围器官及纵隔区域。肿瘤行手术“整块”切除后,组织病理学检查诊断为多形性脂肪肉瘤。鉴于该组织学类型预后不良,患者接受了辅助化疗:多柔比星与异环磷酰胺联合化疗(MAI)。术后9个月,患者肿瘤复发,已无法手术切除。开始姑息化疗,目的是延长这位年轻患者的生命。然而6个月后,患者死于复发性疾病。尽管脂肪肉瘤是一种非常常见的软组织肉瘤,但很少见于胃。标准治疗方法是手术切除。在过去几年中,辅助治疗越来越被接受。首选药物是多柔比星和异环磷酰胺,尽管这种治疗的益处仍大多未知且存在疑问。